Page last updated: 2024-11-05

adamantanecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Adamantanecarboxylic acid (ACA) is a synthetically produced compound that serves as a precursor to the antiviral drug amantadine. ACA itself exhibits antiviral activity against influenza viruses. Its synthesis involves a multi-step process starting from adamantane, a cage-like hydrocarbon. ACA is studied for its potential as a building block in the development of new antiviral drugs and other pharmaceutical applications. ACA is also known for its unique structural properties, which contribute to its antiviral activity. It exhibits a rigid, cage-like structure that restricts conformational changes and makes it less susceptible to enzymatic degradation. This characteristic has led to research exploring its use in drug delivery systems and as a scaffold for developing new pharmaceuticals.'

Cross-References

ID SourceID
PubMed CID13235
CHEMBL ID170568
CHEMBL ID5186120
SCHEMBL ID12714
SCHEMBL ID19557168
SCHEMBL ID19557166
MeSH IDM0059942

Synonyms (68)

Synonym
adamantanecarboxylate
tricyclo(3.3.1.1'3,7)decane-1-carboxylic acid
ai3-52431
3-adamantanecarboxylic acid
nsc 94182
einecs 212-584-6
adamantanecarboxylic acid
nsc 193481
tricyclo[3.3.1.13,7]-decane-1-carboxylic acid
ENAMINE_000586
tricyclo[3.3.1.13,7]-decane-2-carboxylic acid
adamantoic acid
1-carboxyadamantane
nsc94182
tricyclo[3.3.1.13,7]decane-1-carboxylic acid
nsc-94182
1-adamantanecarboxylic acid
OPREA1_849468
adamantane-1-carboxylic acid ,
inchi=1/c11h16o2/c12-10(13)11-4-7-1-8(5-11)3-9(2-7)6-11/h7-9h,1-6h2,(h,12,13
tricyclo[3.3.1.1~3,7~]decane-1-carboxylic acid
828-51-3
STK299270
1-adamantanecarboxylic acid, 99%
AC-10625
A0742
1-adamantoic acid
HMS1395K14
CHEMBL170568 ,
AKOS000119833
AKOS005198690
BP-10550
FT-0607296
PB33810
AKOS017344869
1-adamantanecarboxylate (ac)
bdbm50111977
AM20090817
SCHEMBL12714
FS-2534
(3r,5s,7s)-adamantane-1-carboxylic acid
1-admantanecarboxylic acid
adamantane 1-carboxylic acid
adamantane carboxylic acid
1-adamantyl carboxylic acid
1-adamantylcarboxylic acid
admantane carboxylic acid
adamantylcarboxylic acid
2-adamantane-1-carboxylic acid
tricyclo[3.3.1.1(3,7)-]decane-1-carboxylic acid
tricyclo[3.3.1.1<3,7>]-decane-1-carboxylic acid
1-adamantane-1-carboxylic acid
W-104157
CS-W017189
F3095-4882
mfcd00074720
CHEMBL5186120
SCHEMBL19557168
SCHEMBL19557166
labotest-bb lt00436929
BCP18124
2-(4-methyl-1h-pyrazol-1-yl)propanoicacid
AS-14252
P21153
EN300-16776
GEO-04336
DTXSID40870784
1-adamantanecarboxylic acid (purified by sublimation)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID161445Tested for its inhibitory activity against the enzyme prephenate dehydrogenase (PDH) in Escherichia coli T-protein2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Probing the overlap of chorismate mutase and prephenate dehydrogenase sites in the escherichia coli T-protein: a dehydrogenase-selective inhibitor.
AID52151Tested for its inhibitory activity against the enzyme chorismate mutase (CM) in Escherichia coli T-protein2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Probing the overlap of chorismate mutase and prephenate dehydrogenase sites in the escherichia coli T-protein: a dehydrogenase-selective inhibitor.
AID1879239Antagonist activity at human P2X7 receptor expressed in human 1321N1 cells assessed as reduction in intracellular Ca2+ influx incubated for 30 mins by Fura-2 AM based fluorescence assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders.
AID1879236Antagonist activity at human P2X2 receptor expressed in human 1321N1 cells assessed as reduction in intracellular Ca2+ influx incubated for 30 mins by Fura-2 AM based fluorescence assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders.
AID1879238Antagonist activity at human P2X5 receptor expressed in human 1321N1 cells assessed as reduction in intracellular Ca2+ influx incubated for 30 mins by Fura-2 AM based fluorescence assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders.
AID1879237Antagonist activity at human P2X4 receptor expressed in human 1321N1 cells assessed as reduction in intracellular Ca2+ influx incubated for 30 mins by Fura-2 AM based fluorescence assay relative to control2022European journal of medicinal chemistry, Mar-05, Volume: 231Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (14.29)18.7374
1990's2 (9.52)18.2507
2000's8 (38.10)29.6817
2010's6 (28.57)24.3611
2020's2 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.56 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index42.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]